Header Logo

Connection

THOMAS KOSTEN to Cocaine-Related Disorders

Back to Details
This is a "connection" page, showing publications THOMAS KOSTEN has written about Cocaine-Related Disorders.
THOMAS KOSTEN
Connection Strength
15.935
Cocaine-Related Disorders
  1. Moderation of buprenorphine therapy for cocaine dependence efficacy by variation of the Prodynorphin gene. Eur J Clin Pharmacol. 2022 Jun; 78(6):965-973.
    View in: PubMed
    Score: 0.642
  2. Pharmacogenetics of Dopamine ?-Hydroxylase in cocaine dependence therapy with doxazosin. Addict Biol. 2019 05; 24(3):531-538.
    View in: PubMed
    Score: 0.487
  3. Dopamine D3 receptor-preferring agonist enhances the subjective effects of cocaine in humans. Psychiatry Res. 2015 Nov 30; 230(1):44-9.
    View in: PubMed
    Score: 0.407
  4. Emerging drugs for the treatment of cocaine use disorder: a review of neurobiological targets and pharmacotherapy. Expert Opin Emerg Drugs. 2015 Mar; 20(1):15-29.
    View in: PubMed
    Score: 0.388
  5. The future potential for cocaine vaccines. Expert Opin Biol Ther. 2014 Sep; 14(9):1271-83.
    View in: PubMed
    Score: 0.374
  6. Vaccine for cocaine dependence: a randomized double-blind placebo-controlled efficacy trial. Drug Alcohol Depend. 2014 Jul 01; 140:42-7.
    View in: PubMed
    Score: 0.372
  7. Vaccines against stimulants: cocaine and MA. Br J Clin Pharmacol. 2014 Feb; 77(2):368-74.
    View in: PubMed
    Score: 0.367
  8. Randomized clinical trial of disulfiram for cocaine dependence or abuse during buprenorphine treatment. Drug Alcohol Depend. 2014 Mar 01; 136:36-42.
    View in: PubMed
    Score: 0.364
  9. The ?-opioid receptor gene as a predictor of response in a cocaine vaccine clinical trial. Psychiatr Genet. 2013 Dec; 23(6):225-32.
    View in: PubMed
    Score: 0.363
  10. Prospects, promise and problems on the road to effective vaccines and related therapies for substance abuse. Expert Rev Vaccines. 2013 Mar; 12(3):323-32.
    View in: PubMed
    Score: 0.344
  11. DBH gene as predictor of response in a cocaine vaccine clinical trial. Neurosci Lett. 2013 Apr 29; 541:29-33.
    View in: PubMed
    Score: 0.344
  12. Spontaneous development of IgM anti-cocaine antibodies in habitual cocaine users: effect on IgG antibody responses to a cocaine cholera toxin B conjugate vaccine. Am J Addict. 2013 Mar-Apr; 22(2):169-74.
    View in: PubMed
    Score: 0.342
  13. Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine ?-hydroxylase. Biol Psychiatry. 2013 Feb 01; 73(3):219-24.
    View in: PubMed
    Score: 0.332
  14. Novel pharmacotherapeutic treatments for cocaine addiction. BMC Med. 2011 Nov 03; 9:119.
    View in: PubMed
    Score: 0.314
  15. Sertraline delays relapse in recently abstinent cocaine-dependent patients with depressive symptoms. Addiction. 2012 Jan; 107(1):131-41.
    View in: PubMed
    Score: 0.313
  16. Drug users' adherence to a 6-month vaccination protocol: effects of motivational incentives. Drug Alcohol Depend. 2010 Feb 01; 107(1):76-9.
    View in: PubMed
    Score: 0.272
  17. Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial. Arch Gen Psychiatry. 2009 Oct; 66(10):1116-23.
    View in: PubMed
    Score: 0.272
  18. Vaccines for cocaine abuse. Hum Vaccin. 2009 Apr; 5(4):194-9.
    View in: PubMed
    Score: 0.263
  19. Efficacy of opiate maintenance therapy and adjunctive interventions for opioid dependence with comorbid cocaine use disorders: A systematic review and meta-analysis of controlled clinical trials. Am J Drug Alcohol Abuse. 2009; 35(5):339-49.
    View in: PubMed
    Score: 0.258
  20. Progesterone effects on cocaine use in male cocaine users maintained on methadone: a randomized, double-blind, pilot study. Exp Clin Psychopharmacol. 2007 Oct; 15(5):453-60.
    View in: PubMed
    Score: 0.236
  21. Performance of cocaine dependent individuals and controls on a response inhibition task with varying levels of difficulty. Am J Drug Alcohol Abuse. 2007; 33(5):717-26.
    View in: PubMed
    Score: 0.224
  22. Cue-induced brain activity changes and relapse in cocaine-dependent patients. Neuropsychopharmacology. 2006 Mar; 31(3):644-50.
    View in: PubMed
    Score: 0.212
  23. Emerging pharmacological strategies in the fight against cocaine addiction. Expert Opin Emerg Drugs. 2006 Mar; 11(1):91-8.
    View in: PubMed
    Score: 0.212
  24. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Arch Gen Psychiatry. 2006 Feb; 63(2):219-28.
    View in: PubMed
    Score: 0.211
  25. Cocaine withdrawal symptoms predict medication response in cocaine users. Am J Drug Alcohol Abuse. 2006; 32(4):617-27.
    View in: PubMed
    Score: 0.209
  26. Efficacy of dose and contingency management procedures in LAAM-maintained cocaine-dependent patients. Drug Alcohol Depend. 2005 Aug 01; 79(2):157-65.
    View in: PubMed
    Score: 0.203
  27. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol Psychiatry. 2005 Jul 15; 58(2):158-64.
    View in: PubMed
    Score: 0.203
  28. Cortical excitability in cocaine-dependent patients: a replication and extension of TMS findings. J Psychiatr Res. 2005 May; 39(3):295-302.
    View in: PubMed
    Score: 0.200
  29. Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence. Am J Psychiatry. 2005 Feb; 162(2):340-9.
    View in: PubMed
    Score: 0.197
  30. Novel approaches to the treatment of cocaine addiction. CNS Drugs. 2005; 19(1):13-25.
    View in: PubMed
    Score: 0.195
  31. Desipramine treatment for cocaine dependence in buprenorphine- or methadone-treated patients: baseline urine results as predictor of response. Am J Addict. 2005 Jan-Feb; 14(1):8-17.
    View in: PubMed
    Score: 0.195
  32. Effects of progesterone treatment on cocaine responses in male and female cocaine users. Pharmacol Biochem Behav. 2004 Aug; 78(4):699-705.
    View in: PubMed
    Score: 0.190
  33. Gender-specific vulnerability for rCBF abnormalities among cocaine abusers. Neuroreport. 2004 Apr 09; 15(5):797-801.
    View in: PubMed
    Score: 0.186
  34. Platelet abnormalities associated with cerebral perfusion defects in cocaine dependence. Biol Psychiatry. 2004 Jan 01; 55(1):91-7.
    View in: PubMed
    Score: 0.182
  35. Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: results of a randomized pilot study. Addiction. 2003 Nov; 98(11):1625-32.
    View in: PubMed
    Score: 0.180
  36. Aspirin or amiloride for cerebral perfusion defects in cocaine dependence. Drug Alcohol Depend. 2003 Aug 20; 71(2):187-94.
    View in: PubMed
    Score: 0.178
  37. Comorbid major depressive disorder as a prognostic factor in cocaine-abusing buprenorphine-maintained patients treated with desipramine and contingency management. Am J Drug Alcohol Abuse. 2003 Aug; 29(3):497-514.
    View in: PubMed
    Score: 0.177
  38. Prediction of treatment outcome by baseline urine cocaine results and self-reported cocaine use for cocaine and opioid dependence. Am J Drug Alcohol Abuse. 2003; 29(4):713-27.
    View in: PubMed
    Score: 0.170
  39. Cerebral perfusion defects in combined cocaine and alcohol dependence. Drug Alcohol Depend. 2002 Sep 01; 68(1):95-104.
    View in: PubMed
    Score: 0.166
  40. Sensory gating and psychosis vulnerability in cocaine-dependent individuals: preliminary data. Biol Psychiatry. 2002 Apr 15; 51(8):683-6.
    View in: PubMed
    Score: 0.162
  41. Ketoconazole increases cocaine and opioid use in methadone maintained patients. Drug Alcohol Depend. 2002 Apr 01; 66(2):173-80.
    View in: PubMed
    Score: 0.161
  42. Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine. 2002 Jan 15; 20(7-8):1196-204.
    View in: PubMed
    Score: 0.159
  43. Utility of crossover designs in clinical trials: efficacy of desipramine vs. placebo in opioid-dependent cocaine abusers. Am J Addict. 2002; 11(2):111-23.
    View in: PubMed
    Score: 0.159
  44. Isradipine enhancement of cerebral blood flow in abstinent cocaine abusers with and without chronic perfusion deficits. Am J Addict. 2002; 11(3):200-8.
    View in: PubMed
    Score: 0.159
  45. Effects of cocaine prior to and during bupropion maintenance in cocaine-abusing volunteers. Drug Alcohol Depend. 2001 Jul 01; 63(2):155-67.
    View in: PubMed
    Score: 0.153
  46. Going from the bedside back to the bench with ecopipam: a new strategy for cocaine pharmacotherapy development. Psychopharmacology (Berl). 2001 Jun; 155(4):327-9.
    View in: PubMed
    Score: 0.152
  47. The OPRD1 rs678849 variant influences outcome of disulfiram treatment for cocaine dependency in methadone-maintained patients. Psychiatr Genet. 2021 06 01; 31(3):88-94.
    View in: PubMed
    Score: 0.152
  48. Quantitative medial temporal lobe brain morphology and hypothalamic-pituitary-adrenal axis function in cocaine dependence: a preliminary report. Drug Alcohol Depend. 2001 Mar 01; 62(1):49-56.
    View in: PubMed
    Score: 0.150
  49. A randomized controlled trial of auricular acupuncture for cocaine dependence. Arch Intern Med. 2000 Aug 14-28; 160(15):2305-12.
    View in: PubMed
    Score: 0.144
  50. Significant interaction between clozapine and cocaine in cocaine addicts. Drug Alcohol Depend. 2000 May 01; 59(2):153-63.
    View in: PubMed
    Score: 0.141
  51. Doxazosin treatment in cocaine use disorder: pharmacogenetic response based on an alpha-1 adrenoreceptor subtype D genetic variant. Am J Drug Alcohol Abuse. 2020; 46(2):184-193.
    View in: PubMed
    Score: 0.138
  52. Neurobiological adaptations to psychostimulants and opiates as a basis of treatment development. Ann N Y Acad Sci. 2000; 909:51-87.
    View in: PubMed
    Score: 0.138
  53. Current concepts in pharmacotherapy of substance abuse. Curr Psychiatry Rep. 1999 Dec; 1(2):172-8.
    View in: PubMed
    Score: 0.137
  54. Desipramine in opioid-dependent cocaine abusers maintained on buprenorphine vs methadone. Arch Gen Psychiatry. 1999 Sep; 56(9):812-20.
    View in: PubMed
    Score: 0.135
  55. Pharmacogenetic role of dopamine transporter (SLC6A3) variation on response to disulfiram treatment for cocaine addiction. Am J Addict. 2019 07; 28(4):311-317.
    View in: PubMed
    Score: 0.132
  56. FAAH variant Pro129Thr modulates subjective effects produced by cocaine administration. Am J Addict. 2018 10; 27(7):567-573.
    View in: PubMed
    Score: 0.126
  57. A preliminary investigation of lamotrigine for cocaine abuse in HIV-seropositive patients. Am J Drug Alcohol Abuse. 1998 Feb; 24(1):85-101.
    View in: PubMed
    Score: 0.121
  58. Prognostic factors in Buprenorphine- versus methadone-maintained patients. J Nerv Ment Dis. 1998 Jan; 186(1):35-43.
    View in: PubMed
    Score: 0.120
  59. Pharmacotherapy of cerebral ischemia in cocaine dependence. Drug Alcohol Depend. 1998 Jan 01; 49(2):133-44.
    View in: PubMed
    Score: 0.120
  60. Moderators of response to sertraline versus placebo among recently abstinent, cocaine dependent patients: A retrospective analysis of two clinical trials. Am J Addict. 2017 Dec; 26(8):807-814.
    View in: PubMed
    Score: 0.119
  61. Altered anterior cingulate cortex to hippocampus effective connectivity in response to drug cues in men with cocaine use disorder. Psychiatry Res Neuroimaging. 2018 01 30; 271:59-66.
    View in: PubMed
    Score: 0.119
  62. Association between self-report of cognitive impairment, HIV status, and cocaine use in a sample of cocaine-dependent methadone-maintained patients. Addict Behav. 1997 Sep-Oct; 22(5):599-611.
    View in: PubMed
    Score: 0.118
  63. The a-1 adrenoceptor (ADRA1A) genotype moderates the magnitude of acute cocaine-induced subjective effects in cocaine-dependent individuals. Pharmacogenet Genomics. 2016 09; 26(9):428-35.
    View in: PubMed
    Score: 0.110
  64. Genetic variation of the dopamine transporter (DAT1) influences the acute subjective responses to cocaine in volunteers with cocaine use disorders. Pharmacogenet Genomics. 2015 Jun; 25(6):296-304.
    View in: PubMed
    Score: 0.101
  65. Inhibitory behavioral control: A stochastic dynamic causal modeling study comparing cocaine dependent subjects and controls. Neuroimage Clin. 2015; 7:837-47.
    View in: PubMed
    Score: 0.099
  66. The influence of dopamine ?-hydroxylase gene polymorphism rs1611115 on levodopa/carbidopa treatment for cocaine dependence: a preliminary study. Pharmacogenet Genomics. 2014 Jul; 24(7):370-3.
    View in: PubMed
    Score: 0.094
  67. Clinical efficacy of sertraline alone and augmented with gabapentin in recently abstinent cocaine-dependent patients with depressive symptoms. J Clin Psychopharmacol. 2014 Apr; 34(2):234-9.
    View in: PubMed
    Score: 0.093
  68. ANKK1 and DRD2 pharmacogenetics of disulfiram treatment for cocaine abuse. Pharmacogenet Genomics. 2013 Jul; 23(7):333-40.
    View in: PubMed
    Score: 0.088
  69. The impact of disulfiram treatment on the reinforcing effects of cocaine: a randomized clinical trial. PLoS One. 2012; 7(11):e47702.
    View in: PubMed
    Score: 0.084
  70. Noradrenergic a1 receptor antagonist treatment attenuates positive subjective effects of cocaine in humans: a randomized trial. PLoS One. 2012; 7(2):e30854.
    View in: PubMed
    Score: 0.080
  71. Vaccines against drug abuse. Clin Pharmacol Ther. 2012 Jan; 91(1):60-70.
    View in: PubMed
    Score: 0.079
  72. Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine. Am J Drug Alcohol Abuse. 2009; 35(3):161-77.
    View in: PubMed
    Score: 0.064
  73. Preliminary study of buprenorphine and bupropion for opioid-dependent smokers. Am J Addict. 2008 Jul-Aug; 17(4):287-92.
    View in: PubMed
    Score: 0.062
  74. Treatment outcome predictors for cocaine dependence. Am J Drug Alcohol Abuse. 2007; 33(2):191-206.
    View in: PubMed
    Score: 0.056
  75. Human laboratory and neuroimaging studies in substance use disorders: developing new treatment approaches. Am J Drug Alcohol Abuse. 2007; 33(6):765-7.
    View in: PubMed
    Score: 0.056
  76. Genetics of dopamine and its contribution to cocaine addiction. Behav Genet. 2007 Jan; 37(1):119-45.
    View in: PubMed
    Score: 0.055
  77. Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine dependent methadone-treated patients. Drug Alcohol Depend. 2007 Feb 23; 87(1):1-9.
    View in: PubMed
    Score: 0.055
  78. Antisocial personality and stress-induced brain activation in cocaine-dependent patients. Neuroreport. 2006 Feb 27; 17(3):243-7.
    View in: PubMed
    Score: 0.053
  79. Neural activity associated with stress-induced cocaine craving: a functional magnetic resonance imaging study. Psychopharmacology (Berl). 2005 Dec; 183(2):171-80.
    View in: PubMed
    Score: 0.052
  80. Sex differences in brain activation during stress imagery in abstinent cocaine users: a functional magnetic resonance imaging study. Biol Psychiatry. 2005 Mar 01; 57(5):487-94.
    View in: PubMed
    Score: 0.049
  81. Therapeutic vaccines for substance dependence. Expert Rev Vaccines. 2004 Feb; 3(1):11-8.
    View in: PubMed
    Score: 0.046
  82. Disulfiram facilitates the development and expression of locomotor sensitization to cocaine in rats. Biol Psychiatry. 2003 Nov 01; 54(9):915-21.
    View in: PubMed
    Score: 0.045
  83. Effects of naltrexone and isradipine, alone or in combination, on cocaine responses in humans. Pharmacol Biochem Behav. 2003 Jul; 75(4):801-8.
    View in: PubMed
    Score: 0.044
  84. Therapeutic vaccines for substance dependence. Expert Rev Vaccines. 2002 Oct; 1(3):363-71.
    View in: PubMed
    Score: 0.042
  85. Office-based treatment for opioid dependence: reaching new patient populations. Am J Psychiatry. 2001 Aug; 158(8):1200-4.
    View in: PubMed
    Score: 0.039
  86. Quantitative morphology of the caudate and putamen in patients with cocaine dependence. Am J Psychiatry. 2001 Mar; 158(3):486-9.
    View in: PubMed
    Score: 0.037
  87. Sex differences in self-reported and physiological response to oral cocaine and placebo in humans. Am J Drug Alcohol Abuse. 2000 Nov; 26(4):643-57.
    View in: PubMed
    Score: 0.037
  88. Elevated central serotonin transporter binding availability in acutely abstinent cocaine-dependent patients. Am J Psychiatry. 2000 Jul; 157(7):1134-40.
    View in: PubMed
    Score: 0.036
  89. Thrice-weekly versus daily buprenorphine maintenance. Biol Psychiatry. 2000 Jun 15; 47(12):1072-9.
    View in: PubMed
    Score: 0.036
  90. Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: a preliminary trial. Biol Psychiatry. 2000 Jun 15; 47(12):1080-6.
    View in: PubMed
    Score: 0.036
  91. Disulfiram effects on acute cocaine administration. Drug Alcohol Depend. 1998 Sep 01; 52(1):27-39.
    View in: PubMed
    Score: 0.031
  92. Concurrent use of cocaine and alcohol is more potent and potentially more toxic than use of either alone--a multiple-dose study. Biol Psychiatry. 1998 Aug 15; 44(4):250-9.
    View in: PubMed
    Score: 0.031
  93. Addiction as a brain disease. Am J Psychiatry. 1998 Jun; 155(6):711-3.
    View in: PubMed
    Score: 0.031
  94. Elevated striatal dopamine transporters during acute cocaine abstinence as measured by [123I] beta-CIT SPECT. Am J Psychiatry. 1998 Jun; 155(6):832-4.
    View in: PubMed
    Score: 0.031
  95. The pharmacotherapy of relapse prevention using anticonvulsants. Am J Addict. 1998; 7(3):205-9.
    View in: PubMed
    Score: 0.030
  96. Anti-cocaine antibody and butyrylcholinesterase-derived cocaine hydrolase exert cooperative effects on cocaine pharmacokinetics and cocaine-induced locomotor activity in mice. Chem Biol Interact. 2013 Mar 25; 203(1):212-6.
    View in: PubMed
    Score: 0.021
  97. Effects of anti-cocaine vaccine and viral gene transfer of cocaine hydrolase in mice on cocaine toxicity including motor strength and liver damage. Chem Biol Interact. 2013 Mar 25; 203(1):208-11.
    View in: PubMed
    Score: 0.021
  98. Probing cocaine-antibody interactions in buffer and human serum. PLoS One. 2012; 7(7):e40518.
    View in: PubMed
    Score: 0.021
  99. Clinical efficacy of citalopram alone or augmented with bupropion in methadone-stabilized patients. Am J Addict. 2007 May-Jun; 16(3):187-94.
    View in: PubMed
    Score: 0.014
  100. Treatment of patients with substance use disorders, second edition. American Psychiatric Association. Am J Psychiatry. 2007 Apr; 164(4 Suppl):5-123.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.